Benjamin Arthur De Burgh Bradley

Title: The Innovations of Benjamin Arthur De Burgh Bradley

Introduction

Benjamin Arthur De Burgh Bradley is a notable inventor based in Winterbourne Down, GB. He has made significant contributions to the field of immunology, particularly in the development of human monoclonal antibodies. With a total of 2 patents, his work has implications for blood typing and the prevention of hemolytic disease in newborns.

Latest Patents

Bradley's latest patents include the invention of human anti-Rh(D) monoclonal antibodies. The first patent describes antibodies that bind to the Rh(D) antigen while not interacting with other antigens of the Rh blood group system. These antibodies are characterized as IgG1 proteins with kappa light chains and specific allotypes. They are designed for Rh-typing of red blood cells and for passive immunization to prevent hemolytic disease of the newborn. The second patent also focuses on human anti-Rh(D) monoclonal antibodies, but these are classified as IgG3 proteins with a different allotype, G3m(21). Both patents exemplify the monoclonal antibodies of specific cell lines deposited at the European Collection of Animal Cell Cultures.

Career Highlights

Bradley is associated with the National Blood Authority, where he applies his expertise in immunology and antibody development. His work has been instrumental in advancing the understanding and application of monoclonal antibodies in clinical settings.

Collaborations

He has collaborated with notable colleagues such as Alan Doyle and Belinda Mary Kumpel, contributing to the collective knowledge and advancements in the field of blood immunology.

Conclusion

Benjamin Arthur De Burgh Bradley's innovative work in the development of human monoclonal antibodies has made a significant impact on medical science. His contributions continue to influence practices in blood typing and immunization.